Rosen Law Firm urges ADMA Biologics investors to act by August 10, 2026 to secure lead plaintiff role in securities fraud class action

Executive summary: Rosen Law Firm reminded investors who bought ADMA Biologics (NASDAQ: ADMA) shares between August 9, 2024 and March 25, 2026 that they have until August 10, 2026 to apply as lead plaintiff in a securities fraud class action. The lead plaintiff appointment influences litigation strategy, potential settlement amounts, and the allocation of legal costs, directly affecting shareholder outcomes.

Who is involved: Rosen Law Firm, ADMA Biologics Inc., investors who purchased ADMA securities during the defined class period, and the federal court overseeing the class action.

Likely next: Investors must submit lead plaintiff applications by the August 10, 2026 deadline; thereafter the court will evaluate motions and appoint a lead plaintiff, after which pretrial proceedings will proceed.

On July 18, 2026, Rosen Law Firm issued a reminder that purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 have until August 10, 2026 to file lead plaintiff applications in a securities fraud class action. The notice repeats earlier alerts about the same deadline and class period, underscoring the approaching procedural cutoff. No new allegations were introduced; the communication serves to inform investors of their rights and the impending deadline.

Timeline

2026-07-18 — ADMA Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
2026-07-18 — ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)

Analysis — what this means

Likely next events

August 10, 2026: Deadline for lead plaintiff applications in the ADMA Biologics securities class action.
August 11–15, 2026: Court expected to review lead plaintiff motions and consider appointments.
September 2026: Potential scheduling of a preliminary conference and discovery phase if a lead plaintiff is appointed.

Sectors affected

Biologics manufacturing
Specialty pharmaceuticals
Nasdaq-listed biotech

Regulatory implications

Potential SEC enforcement actions under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 if fraud is substantiated.
Impact on ADMA's internal controls compliance under the Sarbanes-Oxley Act.

Historical parallels

July 12, 2026: Rosen Law Firm first reminded investors of the ADMA Biologics securities fraud lawsuit and the upcoming August 10, 2026 lead plaintiff deadline.
July 14, 2026: Court news announced that a securities fraud class action had been filed on behalf of ADMA Biologics investors after the stock dropped 29% following Culper Research channel‑stuffing allegations.